Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) announced the closing of a non-brokered private placement with Sorbie Bornholm LP and Sorbie Investments LLP, securing a notional subscription amount of approximately CAD$5 million. The financing, structured as a share-purchase agreement, involves the issuance of 7.94 million units at a notional price of CAD$0.63 per unit. Each unit consists of one common share and one warrant exercisable at CAD$0.77 for a three-year period.
The proceeds will be made available to the company through an 18-month sharing arrangement tied to the volume-weighted average trading price of its shares, with monthly settlement amounts varying based on market performance. This structure provides Onco-Innovations with flexible access to capital while aligning investor returns with share price performance.
Onco-Innovations said it intends to use the net proceeds to advance development of its ONC010 program, including manufacturing and preclinical activities, support continued development of its SynoGraph platform, and provide working capital for general corporate purposes. The ONC010 program targets solid tumors, leveraging patented technology for which Onco-Innovations holds an exclusive worldwide license.
This capital infusion is critical for Onco-Innovations as it progresses its oncology pipeline. The company, a Canadian-based entity dedicated to cancer research and treatment, focuses on pioneering research and innovative solutions for the prevention and treatment of cancer. The SynoGraph platform represents a novel approach in oncology, and the additional funding will accelerate its development.
The impact of this financing extends beyond the company. By advancing ONC010 and SynoGraph, Onco-Innovations could bring new treatment options to patients with solid tumors, addressing a significant unmet medical need. For investors, the structured sharing arrangement offers a unique mechanism that ties returns to the company's market performance, potentially aligning long-term interests.
The broader oncology sector may benefit from the progress of these programs, as innovative therapies are needed to improve outcomes for cancer patients. With this capital, Onco-Innovations is positioned to move its preclinical candidates toward clinical trials, a critical step in drug development.
For more details, the full press release is available at https://ibn.fm/1Hrlg. Updates on the company can be found in its newsroom at https://ibn.fm/ONNVF.
